vs
Apellis Pharmaceuticals, Inc.（APLS）与简柏特（EGP）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是简柏特的1.1倍（$199.9M vs $190.3M），简柏特净利率更高（49.7% vs -29.5%，领先79.2%），简柏特同比增速更快（9.1% vs -5.9%），简柏特自由现金流更多（$126.7M vs $-14.3M），过去两年简柏特的营收复合增速更高（9.4% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
简柏特是全球领先的信息技术服务、咨询及外包服务商，总部位于美国纽约，注册地为百慕大，最初创立于印度古尔冈。目前公司全球员工超12.5万名，服务覆盖30余个国家，于纽交所上市，2023年营收达44.8亿美元。
APLS vs EGP — 直观对比
营收规模更大
APLS
是对方的1.1倍
$190.3M
营收增速更快
EGP
高出15.0%
-5.9%
净利率更高
EGP
高出79.2%
-29.5%
自由现金流更多
EGP
多$141.0M
$-14.3M
两年增速更快
EGP
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $190.3M |
| 净利润 | $-59.0M | $94.6M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 49.7% |
| 营收同比 | -5.9% | 9.1% |
| 净利润同比 | -62.2% | 59.2% |
| 每股收益（稀释后） | $-0.40 | $1.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEGP
| Q1 26 | — | $190.3M | ||
| Q4 25 | $199.9M | $187.5M | ||
| Q3 25 | $458.6M | $182.1M | ||
| Q2 25 | $178.5M | $177.3M | ||
| Q1 25 | $166.8M | $174.4M | ||
| Q4 24 | $212.5M | $164.0M | ||
| Q3 24 | $196.8M | $162.9M | ||
| Q2 24 | $199.7M | $159.1M |
净利润APLSEGP
| Q1 26 | — | $94.6M | ||
| Q4 25 | $-59.0M | $67.8M | ||
| Q3 25 | $215.7M | $67.0M | ||
| Q2 25 | $-42.2M | $63.3M | ||
| Q1 25 | $-92.2M | $59.4M | ||
| Q4 24 | $-36.4M | $58.7M | ||
| Q3 24 | $-57.4M | $55.2M | ||
| Q2 24 | $-37.7M | $55.3M |
营业利润率APLSEGP
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — |
净利率APLSEGP
| Q1 26 | — | 49.7% | ||
| Q4 25 | -29.5% | 36.1% | ||
| Q3 25 | 47.0% | 36.8% | ||
| Q2 25 | -23.6% | 35.7% | ||
| Q1 25 | -55.3% | 34.1% | ||
| Q4 24 | -17.1% | 35.8% | ||
| Q3 24 | -29.2% | 33.9% | ||
| Q2 24 | -18.9% | 34.8% |
每股收益（稀释后）APLSEGP
| Q1 26 | — | $1.77 | ||
| Q4 25 | $-0.40 | $1.27 | ||
| Q3 25 | $1.67 | $1.26 | ||
| Q2 25 | $-0.33 | $1.20 | ||
| Q1 25 | $-0.74 | $1.14 | ||
| Q4 24 | $-0.30 | $1.17 | ||
| Q3 24 | $-0.46 | $1.13 | ||
| Q2 24 | $-0.30 | $1.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $31.4M |
| 总债务越低越好 | — | $1.6B |
| 股东权益账面价值 | $370.1M | $3.6B |
| 总资产 | $1.1B | $5.5B |
| 负债/权益比越低杠杆越低 | — | 0.45× |
8季度趋势，按日历期对齐
现金及短期投资APLSEGP
| Q1 26 | — | $31.4M | ||
| Q4 25 | $466.2M | $1.0M | ||
| Q3 25 | $479.2M | $3.0M | ||
| Q2 25 | $370.0M | $32.9M | ||
| Q1 25 | $358.4M | $20.5M | ||
| Q4 24 | $411.3M | $17.5M | ||
| Q3 24 | $396.9M | $17.0M | ||
| Q2 24 | $360.1M | $39.4M |
总债务APLSEGP
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.7B |
股东权益APLSEGP
| Q1 26 | — | $3.6B | ||
| Q4 25 | $370.1M | $3.5B | ||
| Q3 25 | $401.2M | $3.5B | ||
| Q2 25 | $156.3M | $3.4B | ||
| Q1 25 | $164.2M | $3.3B | ||
| Q4 24 | $228.5M | $3.3B | ||
| Q3 24 | $237.1M | $2.8B | ||
| Q2 24 | $264.3M | $2.8B |
总资产APLSEGP
| Q1 26 | — | $5.5B | ||
| Q4 25 | $1.1B | $5.4B | ||
| Q3 25 | $1.1B | $5.4B | ||
| Q2 25 | $821.4M | $5.2B | ||
| Q1 25 | $807.3M | $5.1B | ||
| Q4 24 | $885.1M | $5.1B | ||
| Q3 24 | $901.9M | $4.8B | ||
| Q2 24 | $904.5M | $4.7B |
负债/权益比APLSEGP
| Q1 26 | — | 0.45× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.41× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $142.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $126.7M |
| 自由现金流率自由现金流/营收 | -7.1% | 66.6% |
| 资本支出强度资本支出/营收 | 0.1% | 8.2% |
| 现金转化率经营现金流/净利润 | — | 1.50× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $771.1M |
8季度趋势，按日历期对齐
经营现金流APLSEGP
| Q1 26 | — | $142.3M | ||
| Q4 25 | $-14.2M | $480.7M | ||
| Q3 25 | $108.5M | $138.9M | ||
| Q2 25 | $4.4M | $143.4M | ||
| Q1 25 | $-53.4M | $133.7M | ||
| Q4 24 | $19.4M | $416.6M | ||
| Q3 24 | $34.1M | $122.9M | ||
| Q2 24 | $-8.3M | $122.9M |
自由现金流APLSEGP
| Q1 26 | — | $126.7M | ||
| Q4 25 | $-14.3M | $404.9M | ||
| Q3 25 | $108.3M | $120.3M | ||
| Q2 25 | $4.4M | $119.2M | ||
| Q1 25 | $-53.4M | $113.9M | ||
| Q4 24 | $19.3M | $357.3M | ||
| Q3 24 | — | $108.5M | ||
| Q2 24 | $-8.4M | $102.8M |
自由现金流率APLSEGP
| Q1 26 | — | 66.6% | ||
| Q4 25 | -7.1% | 216.0% | ||
| Q3 25 | 23.6% | 66.0% | ||
| Q2 25 | 2.5% | 67.2% | ||
| Q1 25 | -32.0% | 65.3% | ||
| Q4 24 | 9.1% | 217.8% | ||
| Q3 24 | — | 66.6% | ||
| Q2 24 | -4.2% | 64.6% |
资本支出强度APLSEGP
| Q1 26 | — | 8.2% | ||
| Q4 25 | 0.1% | 40.5% | ||
| Q3 25 | 0.0% | 10.2% | ||
| Q2 25 | 0.0% | 13.7% | ||
| Q1 25 | 0.0% | 11.3% | ||
| Q4 24 | 0.0% | 36.1% | ||
| Q3 24 | 0.0% | 8.9% | ||
| Q2 24 | 0.0% | 12.6% |
现金转化率APLSEGP
| Q1 26 | — | 1.50× | ||
| Q4 25 | — | 7.10× | ||
| Q3 25 | 0.50× | 2.07× | ||
| Q2 25 | — | 2.26× | ||
| Q1 25 | — | 2.25× | ||
| Q4 24 | — | 7.10× | ||
| Q3 24 | — | 2.23× | ||
| Q2 24 | — | 2.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EGP
暂无分部数据
